RCT of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Ocular Adnexal MALT Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
Rescue of Nephrons With ALE.F02 (RENAL-F02)
- Status
- RECRUITING
- Phase
- PHASE2
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
- Status
- RECRUITING
- Phase
- PHASE2
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
- Status
- RECRUITING
- Phase
- PHASE4
Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia
- Status
- WITHDRAWN
- Phase
- PHASE4
Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis
- Status
- RECRUITING
- Phase
- PHASE4
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia
- Status
- RECRUITING
- Phase
- PHASE2
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE3
Rituxmab Versus IL-6 in Treating ILD
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Status
- RECRUITING
- Phase
- PHASE3
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE1
An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement
- Status
- RECRUITING
- Phase
- PHASE2